标 志 性 成 果 |
杨利军,教授,博士生导师,博士后指导教师,山西省学术技术带头人,山西省中青年拔尖创新人才,山西省高校优秀青年学术带头人。现担任山西医科大学科学技术部部长、医学科学院常务副院长,兼任山西省医学会科研管理分会候任主任委员、中国高等教育学会科技管理研究分会理事、山西省专利保护协会常务理事,山西省药学会应用药理学专业委员会副主任委员等职务。主要研究方向是小分子多肽靶向药物研究和肿瘤免疫分子生物学研究。先后承担国家十二五重大新药创制课题、国家自然科学基金等多项国家级科研项目,主持山西省重点研发计划重点项目等省部级课题10余项,获省级科技奖励10余项,发表各类学术论文 60 多篇。 1. Qi Zhao, Xing Lv, Yanqun Dong, Hanyu Hong, Yanbo Zheng, Lijun Yang*, Jianhua Gong*. IMB5036 overcomes resistance to multiple chemotherapeutic drugs in human cancer cells through pyroptosis by targeting the KH-type splicing regulatory protein. Life Sciences, 2023, 328:121941 2. Qi Zhao, Yanbo Zheng, Xing Lv, Jianhua Gong,Liju Yang*.IMB5036 inhibits human pancreati c cancer growth primarily through activating necroptosis, Basic Clin Pharmacol Toxicol, 2021, 130 (3): 375-384 3. Chen Junjun, Dai Jie, Kang Zhiming, Yang Ting, Zhao Qi, Zheng Jinxiu, Zhang Xinxin, Zhang Jisheng, Xu Jun, Sun Gongqin,Yang Lijun*,Yang Tao*. A combinatorial strategy for ov ercoming primary and acquired resistance of MEK inhibition in colorectal cancer, Experimental Cell Research, 2020, 393(1): 1-10 4. Lijun Yang, Yutao Wang, Haifeng Zheng,Dong Zhang, Xiangwei Wu, Gongqin Sun, Tao Yang*. Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-de pendent mechanisms, Journal of Chemotherapy, 2017, 29(3): 179-188 5. Lijun Yang, Litao Zhang, Lihong Yan, Haifeng Zheng, Peifen Lu, Junjun Chen, Jie Dai, Haibiao Sun, Yong Xu,Tao Yang*. Stability assessment of a new antithrombotic small peptide, Arg-Gly- Asp-Trp-Arg (RGDWR), and its derivative, Biotechnology Letters, 2017, 39(8): 1183-1190 |